Neuropathy and Anti-GFAP Antibodies

Neurological Diseases or Conditions Clinical Trial

— Neuro-GFAP  

Official title:

Study of the Consequences of Anti-GFAP Antibodies on the Peripheral Nervous System

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05742087
• Other study ID #: 22-5018
• Status: Active, not recruiting
• Start date: September 1, 2022
• Est. completion date: May 1, 2023

Study information

• Verified date: February 2023
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Anti-Glial Fibrillary Acidic Protein (GFAP) are antibodies associated to inflammatory diseases of the central nervous system. The GFAP protein is highly expressed by astrocytes explaining these syndromes, but GFAP is also expressed by immature and non-myelinating Schwann cells. Thus, these antibodies could also lead to damages of the peripheral nervous system (PNS). Moreover, such damages have already been reported on small studies, and there is a need for larger cohorts.

The investigators will use the cohort of patients with neurological syndromes and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the "Reference center for paraneoplastic neurological syndromes and autoimmune encephalitis" to determine the frequency of the PNS involvement in these patients.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 120
• Est. completion date: May 1, 2023
• Est. primary completion date: October 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• - Age > 18 years old

• Neurological symptoms

• Anti-GFAP antibodies identified in the CSF

Exclusion Criteria:

• - Uncomplete data in the medical records of patients

Related Conditions & MeSH terms

• Nervous System Diseases
• Neurological Diseases or Conditions

Intervention

Other:
• Clinical examination
The examination performed by the clinician of the patient will be analyzed from the cohort as previously explained.
• electroneuromyography (ENMG)
Data from the ENMGs will be extracted from the cohort and analyzed.

Locations

Country	Name	City	State
France	Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cranial nerves abnormality at clinical examination of abnormal ENMG	Data concerning the clinical examination and the ENMG will be extracted from the cohort of patients with neurological syndroms and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the "Centre de reference des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes".	Immediately after diagnosis